< Return back to Press Releases
Bridge Laboratories Awarded Major Contract to Support the
National Institute on Drug Abuse (NIDA)
Gaithersburg, MD – (October 7, 2008)
Bridge Global Pharmaceutical Services, Inc., doing business as Bridge Laboratories, announced today that it has been awarded a follow-on contract by the National Institute on Drug Abuse (NIDA). The single award contract has a five-year base period of performance for an estimated value of $4.1 million if all options are exercised. Under the new contract, Bridge will provide toxicological evaluations for potential medications used to treat drug abuse¹.
"We appreciate the confidence NIDA has shown in Bridge Laboratories over the past five years and look forward to collaborating with them to find ways to significantly improve prevention, treatment, and policy as it relates to drug abuse and addiction," said Tom Oakley, President and CEO, Bridge Laboratories.
Bridge has a long history of working with the US government and commercial clients in the development of safe drugs and biologics.
About Pharmaron
Founded in 2003, Pharmaron is a leading pharmaceutical and biotechnology drug R&D CRO, with operations in China and the United States. Clients include pharmaceutical, biotechnology, academic and government organizations. As a research-driven and customer-focused company, Pharmaron provides a broad, integrated portfolio of laboratory and manufacturing services from drug discovery to IND submission. These services are designed to help its global partners improve the success of research and shorten the time of development cost effectively in discovering and developing drugs. For more information about Pharmaron, please visit http://www.pharmaron.com.
|
